Abstract:Introduction: Luteolin is a flavonoid polyphenolic compound exerting broad pharmacological and medicinal properties. Diabetes-related obesity increases the total blood volume and cardiac output and may increase the myocardial hypertrophy progression. However, the mechanism of luteolin in diabetic myocardial hypertrophy remains uncertain. Therefore, this study aimed to evaluate whether luteolin improved diabetic cardiomyopathy (DCM) by inhibiting the proteasome activity. Methods: Cardiomyopathy was induced in streptozotocin-treated diabetes mellitus (DM) and db/db mice. Luteolin (20 mg kg −1 ·day −1 ) was administrated via gavage for 12 weeks. In vitro , high glucose and high insulin (HGI, glucose at 25.5 mM and insulin at 0.1 μM) inducing primary neonatal rat cardiomyocytes (NRCMs) were treated with or without luteolin for 48 h. Echocardiography, reverse transcription quantitative polymerase chain reaction, histology, immunofluorescence, and Western blotting were conducted. Proteasome activities were also detected using a fluorescent peptide substrate. Results: Luteolin administration significantly prevented the onset of cardiac hypertrophy, fibrosis, and dysfunction in type 1 DM (T1DM) and type 2 DM (T2DM). Compared with DCM mice, luteolin groups showed lower serum triglyceride and total cholesterol levels. Furthermore, luteolin attenuated HGI-induced myocardial hypertrophy and reduced atrial natriuretic factor mRNA level in NRCMs. Proteasome activities were inhibited by luteolin in vitro. Luteolin also reduces the proteasome subunit levels (PSMB) 1, PSMB2, and PSMB5 of the 20S proteasome, as well as proteasome-regulated particles (Rpt) 1 and Rpt4 levels of 19S proteasome. Furthermore, luteolin treatment increased protein kinase B (AKT) and GSK-3α/β (inactivation of GSK-3) phosphorylation. The phosphorylation level of AMPK activity was also reversed after the treatment with luteolin in comparison with the HGI-treated group. Conclusion: This study indicates that luteolin protected against DCM in mice, including T1DM and T2DM, by upregulating phosphorylated protein AMPK and AKT/GSK-3 pathways while decreasing the proteasome activity. These findings suggest that luteolin may be a potential therapeutic agent for DCM. Pharmacology

Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity

Luteolin Targets the Toll-Like Receptor Signaling Pathway in Prevention of Hepatic and Adipocyte Fibrosis and Insulin Resistance in Diet-Induced Obese Mice

LUTEOLIN REDUCES CARDIAC DYSFUNCTIONS AND MITOCHONDRIAL OXIDATIVE STRESS IN STREPTOZOTOCIN‐INDUCED DIABETIC RATS

[Luteolin Reduces Cardiac Dysfunctions in Streptozotocin-Induced Diabetic Rats].

Cardioprotective Effects of Luteolin on Ischemia/reperfusion Injury in Diabetic Rats Are Modulated by Enos and the Mitochondrial Permeability Transition Pathway.

Luteolin Protects Against High Fat Diet-Induced Cognitive Deficits in Obesity Mice.

Lutein Prevents High Fat Diet-Induced Atherosclerosis in ApoE-Deficient Mice by Inhibiting NADPH Oxidase and Increasing PPAR Expression

Luteolin alleviates muscle atrophy, mitochondrial dysfunction and abnormal FNDC5 expression in high fat diet-induced obese rats and palmitic acid-treated C2C12 myotubes

949 OXYGENATED CAROTENOID LUTEIN SUPPLEMENTATION AGAINST EARLY ATHEROSCLEROSIS IN APOE-DEFICIENT MICE THROUGH ALLEVIATION THE DYSLIPIDEMIA AND ATTENUATION THE OXIDATIVE STRESS

Luteolin Reduces Cardiac Damage Caused by Hyperlipidemia in Sprague-Dawley Rats.

Diet Supplementation of Luteolin Before Fatty Liver Formation Improves Hepatic Steatosis in Obese Mice by Inhibiting Visceral Adipose Tissue Lipolysis.

Luteolin Attenuates Diabetic Myocardial Hypertrophy by Inhibiting Proteasome Activity

Luteolin Attenuates Cardiac Ischemia/Reperfusion Injury in Diabetic Rats by Modulating Nrf2 Antioxidative Function

The possible protective effect of luteolin on cardiovascular and hepatic changes in metabolic syndrome rat model

Luteolin Improves Myocardial Cell Glucolipid Metabolism by Inhibiting Hypoxia Inducible Factor-1Α Expression in Angiotensin II/hypoxia-induced Hypertrophic H9c2 Cells.

Low-dose Diet Supplement of a Natural Flavonoid, Luteolin, Ameliorates Diet-Induced Obesity and Insulin Resistance in Mice

Luteolin ameliorates cardiac failure in type I diabetic cardiomyopathy

Luteolin reduces obesity-associated insulin resistance in mice by activating AMPKα1 signalling in adipose tissue macrophages

Lutein Attenuates Excessive Lipid Accumulation in Differentiated 3T3-L1 Cells and Abdominal Adipose Tissue of Rats by the SIRT1-mediated Pathway.

Luteolin ameliorates dextran sulfate sodium-induced colitis in mice possibly through activation of the Nrf2 signaling pathway

Luteolin Ameliorates Hepatic Steatosis and Enhances Mitochondrial Biogenesis Via AMPK/PGC-1α Pathway in Western Diet-Fed Mice.